Ming-ying Zheng

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non-Small Cell Lung Cancer With ROS1 Rearrangement.

Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non-Small Cell Lung Cancer With ROS1 Rearrangement.

Journal: Cancer medicine
Published: April 23, 2025

PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.

PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.

Journal: Science bulletin
Published: September 12, 2023

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial.

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial.

Journal: EClinicalMedicine
Published: July 30, 2023

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer.

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer.

Journal: Journal of thoracic disease
Published: January 31, 2023

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.

Journal: Nature medicine
Published: December 11, 2022

A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.

A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 11, 2022

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes.

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes.

Journal: Journal of cancer research and clinical oncology
Published: May 30, 2022

Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.

Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.

Journal: Clinical lung cancer
Published: June 21, 2021

Clinical features and intervention timing in patients with pregnancy-associated non-small-cell lung cancer.

Clinical features and intervention timing in patients with pregnancy-associated non-small-cell lung cancer.

Journal: Journal of thoracic disease
Published: February 24, 2021

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer.

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer.

Journal: Journal of thoracic disease
Published: November 19, 2020

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 07, 2017
Showing 1-11 of 11

Last Updated: 09/26/2026